Tissue Regenix Group PLC Tissue Regenix adds European bladder matrix patent - RNS Released Pre-Market
July 25 2014 - 11:58AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
25 July 2014
Tissue Regenix Group Plc
Tissue Regenix adds European bladder matrix patent to global
exclusive licence portfolio
YORK, 25 July 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue
Regenix" or "the Group"), the regenerative medical devices company,
has received a decision to grant a European patent covering the use
of its dCELL(R) technology in creating tissue implants for bladder
repair.
The Group has exclusive access to a range of patents protecting
its core processes in major markets, and is adding to these by
working with its technology partner, the University of Leeds, to
protect individual products and processes.
Tissue Regenix's dCELL(R) decellularisation process removes DNA
and other cellular material from animal and human tissue leaving an
acellular tissue scaffold, which is not rejected by the patient's
body, and which can then be used to repair diseased or worn-out
body parts.
This is the latest patent covering the use of the dCELL(R)
decellularisation process and follows a recent announcement in May
2014 that a similar patent, related to tissue matrices for bladder
implantation, has been granted in the United States.
Antony Odell, CEO of Tissue Regenix commented: "The global
urology device market is one of the largest growth areas for the
medical devices industry, and is estimated to be worth $8.6bn by
2022,[1] driven by treatment demands for an ageing population."
"As part of the global roll-out of our dCELL(R) technology, this
latest European bladder patent adds to our ever-growing global
portfolio, and helps Tissue Regenix achieve our aim of
commercialising new ways to treat an array of urological
disorders."
Tissue Regenix has offices in the UK and US and is concentrated
on the global commercialisation of its dCELL(R) technology.
ENDS
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Newgate Communications: +44 207 6806550
Andrew Adie
Stephanie Dobbs
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
[1] Urology devices: World market outlook 2012-2022, Visiongain,
November 2012
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRARIMRTMBBTBAI
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024